Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Malignant Solid Tumor × fludarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 206 Precursor Cell Lymphoblastic Leukemia-Lymphoma 125 Myelodysplastic Syndromes 123 Leukemia, Lymphocytic, Chronic, B-Cell 123 Leukemia 105 Multiple Myeloma 100 Lymphoma, Non-Hodgkin 100 Lymphoma 100 Hematologic Neoplasms 68 Recurrence 65 Hodgkin Disease 61 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60 Melanoma 59 Lymphoma, B-Cell 53 Lymphoma, Mantle-Cell 47 Lymphoma, Follicular 46 Lymphoma, Large B-Cell, Diffuse 45 Myeloproliferative Disorders 37 Burkitt Lymphoma 37 Ovarian Neoplasms 35 Neoplasms 32 Lymphoma, B-Cell, Marginal Zone 27 Neoplasm Metastasis 26 Graft vs Host Disease 26 Leukemia, Biphenotypic, Acute 25 Breast Neoplasms 25 Carcinoma, Non-Small-Cell Lung 23 Neoplasms, Plasma Cell 21 Primary Myelofibrosis 20 Pancreatic Neoplasms 20

Interventions

Injections 3 Granulocyte-Macrophage Colony-Stimulating Factor 2 Colony-Stimulating Factors 2 nabiximols 1 fludarabine 1 camrelizumab 1 Radiofrequency Ablation 1 Interleukin-2 1 Immune Checkpoint Inhibitors 1 Cyclophosphamide 1 Adjuvants, Immunologic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03171220 2017-06-06

NRT-01

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2 Unknown

Other solid neoplasm

Advanced Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡